Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




AI Spatial Analysis of Routine Slides Helps Predict Pancreatic Cancer Recurrence

By LabMedica International staff writers
Posted on 11 Sep 2026

Predicting which patients with pancreatic cancer will recur after treatment and surgery remains challenging. More...

Pathology evaluation typically measures residual tumor burden, but recent work found that tumor amount alone did not reliably distinguish higher- from lower-risk patients. The spatial organization of residual cancer within surrounding stroma may add prognostic value, especially when neoadjuvant chemotherapy produces only a limited pathologic response. A new study shows that AI-enabled spatial analysis of routine hematoxylin and eosin (H&E) slides can help identify patients at higher recurrence risk.

Mayo Clinic (Rochester, MN, USA) researchers developed an AI-enabled spatial analysis approach that reads organizational features on standard pathology slides. The method uses an AI tool to identify cancer and stromal regions, then quantifies how those regions form patches, boundaries, and intermixed areas. Investigators adapted techniques from landscape ecology to measure tissue shape, fragmentation, and the degree of cancer-stroma intermixing on H&E slides.

The study analyzed tissue from 203 patients with pancreatic ductal adenocarcinoma who received treatment before surgery but showed only a limited pathologic response. Two spatial signatures predicted disease-free survival even after accounting for stage, lymph node status, and other established clinical and pathologic risk factors. Patients whose residual cancer showed a more fragmented, intermixed pattern with surrounding stroma experienced earlier recurrence, whereas residual tumor amount alone did not reliably stratify risk.

Across models, the AI-derived spatial features improved separation of higher- and lower-risk groups when conventional measures were less informative. In one model, patients classified as high risk had a 71% higher adjusted risk of recurrence; in another, their adjusted risk was more than doubled. These high-risk spatial patterns also showed fewer immune cells within cancer regions, with immune cells tending to cluster around the tumor rather than infiltrate it.

Because the workflow analyzes slides already generated during routine care, it may provide added prognostic information without requiring another tissue test. The study was published in Clinical Cancer Research, and the researchers note that prospective studies are needed before the approach can inform clinical decision-making.

"Current pathology assessments largely tell us how much tumor is left after treatment. We wanted to know whether the geography of that remaining cancer could reveal additional biology about recurrence risk," said Ryan Carr, M.D., Ph.D., a Mayo Clinic oncologist and senior author of the study.

"Our long-term goal is to better identify which patients remain at greatest risk and ultimately use that knowledge to guide more individualized surveillance, adjuvant therapy and clinical trial design," added Carr.

Related Links
Mayo Clinic


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Gold Member
Platelet Function Analyzer
PL-12
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Measuring six variants from one sample may improve research efficiency and support clinical trials of amyloid biology in Alzheimer’s disease and related conditions (Image Credit: Adobe Stock)

Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research

Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.